BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
1. BeiGene discontinued ociperlimab development due to clinical trial termination. 2. Phase 3 trial failed to meet primary endpoint of overall survival. 3. Decision highlights focus on promising candidates; no new safety signals noted. 4. ONC stock dropped 4.2% following the announcement, currently at $263.04.